Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease

International Journal of Cardiology

Volumn 185, Issue , 2015, Pages 263-268

  Yamagishi, Sho Ichi ^a   Fukami, Kei ^a   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Cardiovascular disease (CVD); Diabetes; RAGE; Skin autofluorescence (SAF)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; C REACTIVE PROTEIN; CARNITINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CREATININE; ELASTIN; HIGH DENSITY LIPOPROTEIN; NITRIC OXIDE; BIOLOGICAL MARKER;

AGE DISTRIBUTION; ALBUMINURIA; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; AUTOFLUORESCENCE; AUTOFLUORESCENCE IMAGING; BIOACCUMULATION; BLOOD VESSEL CALCIFICATION; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CELL ACTIVATION; CELL REGENERATION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETIC NEUROPATHY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; METABOLIC DISORDER; MICROANGIOPATHY; MONOCYTE; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; PULSE WAVE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEPSIS; SKIN AUTOFLUORESCENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; VASCULAR DISEASE; VASCULAR RESISTANCE; COMPLICATION; DIABETIC ANGIOPATHY; DISEASE COURSE; METABOLISM; PATHOLOGY; SKIN;

BIOMARKERS; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; SKIN;

EID: 84928235521     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.167     Document Type: Review

References (84)

1. V.M. Monnier Nonenzymatic glycosylation, the Maillard reaction and the aging process J. Gerontol. 45 1990 B105 B111
2. S. Yamagishi Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders Rejuvenation Res. 15 2012 564 572
3. A.M. Schmidt, and D. Stern Atherosclerosis and diabetes: the RAGE connection Curr. Atheroscler. Rep. 2 2000 430 436
4. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr. Pharm. Des. 11 2005 2279 2299
5. H. Vlassara, and G.E. Striker Advanced glycation endproducts in diabetes and diabetic complications Endocrinol. Metab. Clin. N. Am. 42 2013 697 719
6. M.S. Ward, A.K. Fortheringham, M.E. Cooper, and J.M. Forbes Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease Curr. Opin. Pharmacol. 13 2013 654 661
7. K. Fukami, S. Yamagishi, and S. Okuda Role of AGEs-RAGE system in cardiovascular disease Curr. Pharm. Des. 20 2014 2395 2402
8. M. Takeuchi, and S. Yamagishi Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease Curr. Pharm. Des. 14 2008 973 978
9. S. Yamagishi Role of advanced glycation end products (AGEs) in osteoporosis in diabetes Curr. Drug Targets 12 2011 2096 2102
10. S.I. Yamagishi, T. Matsui, and K. Fukami Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk Rejuvenation Res. 18 2015 48 56
11. M. Kajikawa, A. Nakashima, N. Fujimura, T. Maruhashi, Y. Iwamoto, A. Iwamoto, T. Matsumoto, N. Oda, T. Hidaka, Y. Kihara, K. Chayama, C. Goto, Y. Aibara, K. Noma, M. Takeuchi, T. Matsui, S.I. Yamagishi, and Y. Higashi Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function Diabetes Care 38 2015 119 125
12. N. Tahara, S. Yamagishi, M. Takeuchi, A. Honda, A. Tahara, Y. Nitta, N. Kodama, M. Mizoguchi, H. Kaida, M. Ishibashi, N. Hayabuchi, T. Matsui, and T. Imaizumi Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography Diabetes Care 35 2012 2618 2625
13. S. Ueda, S. Yamagishi, T. Matsui, Y. Noda, S. Ueda, Y. Jinnouchi, K. Sasaki, M. Takeuchi, and T. Imaizumi Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects Cardiovasc. Ther. 30 2012 249 254
14. N. Tahara, S. Yamagishi, T. Matsui, M. Takeuchi, Y. Nitta, N. Kodama, M. Mizoguchi, and T. Imaizumi Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects Cardiovasc. Ther. 30 2012 42 48
15. J.K. Sun, H.A. Keenan, J.D. Cavallerano, B.F. Asztalos, E.J. Schaefer, D.R. Sell, C.M. Strauch, V.M. Monnier, A. Doria, L.P. Aiello, and G.L. King Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study Diabetes Care 34 2011 968 974
16. B.K. Kilhovd, A. Juutilainen, S. Lehto, T. Rönnemaa, P.A. Torjesen, K.F. Hanssen, and M. Laakso Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study Diabetologia 50 2007 1409 1417
17. J.W. Nin, A. Jorsal, I. Ferreira, C.G. Schalkwijk, M.H. Prins, H.H. Parving, L. Tarnow, P. Rossing, and C.D. Stehouwer Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study Diabetes Care 34 2011 442 447
18. V.M. Monnier, O. Bautista, D. Kenny, D.R. Sell, J. Fogarty, W. Dahms, P.A. Cleary, J. Lachin, and S. Genuth Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT skin collagen ancillary study group. Diabetes control and complications trial Diabetes 48 1999 870 880
19. S. Genuth, W. Sun, P. Cleary, D.R. Sell, W. Dahms, J. Malone, W. Sivitz, and V.M. Monnier DCCT skin collagen ancillary study group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes Diabetes 54 2005 3103 3111
20. R. Meerwaldt, R. Graaff, P.H. Oomen, T.P. Links, J.J. Jager, N.L. Alderson, S.R. Thorpe, J.W. Baynes, R.O. Gans, and A.J. Smit Simple non-invasive assessment of advanced glycation endproduct accumulation Diabetologia 47 2004 1324 1330
21. D.C. Bos, W.L. de Ranitz-Greven, and H.W. de Valk Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review Diabetes Technol. Ther. 13 2011 773 779
22. S. Arsov, R. Graaff, W. van Oeveren, B. Stegmayr, A. Sikole, G. Rakhorst, and A.J. Smit Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review Clin. Chem. Lab. Med. 52 2014 11 20
23. G. Llauradó, V. Ceperuelo-Mallafré, C. Vilardell, R. Simó, P. Gil, A. Cano, J. Vendrell, and J.M. González-Clemente Advanced glycation end products are associated with arterial stiffness in type 1 diabetes J. Endocrinol. 221 2014 405 413
24. A.S. Januszewski, N. Sachithanandan, C. Karschimkus, D.N. O'Neal, C.K. Yeung, N. Alkatib, and A.J. Jenkins Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction Diabet. Med. 29 2012 726 733
25. G. Watfa, G. Soulis, E. Tartagni, A. Kearney-Schwartz, C. Borghi, P. Salvi, and A. Benetos Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations Diabetes Metab. 38 2012 413 419
26. H. Ueno, H. Koyama, S. Tanaka, S. Fukumoto, K. Shinohara, T. Shoji, M. Emoto, H. Tahara, R. Kakiya, T. Tabata, T. Miyata, and Y. Nishizawa Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease Metabolism 57 2008 1452 1457
27. F. Mac-Way, V. Couture, M.S. Utescu, S. Ignace, S.A. De Serres, R.C. Loignon, K. Marquis, R. Larivière, and M. Agharazii Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis Int. Urol. Nephrol. 46 2014 817 824
28. B. Hofmann, A.C. Adam, K. Jacobs, M. Riemer, C. Erbs, H. Bushnaq, A. Simm, R.E. Silber, and A.N. Santos Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? Exp. Gerontol. 48 2013 38 44
29. S. Willemsen, J.W. Hartog, Y.M. Hummel, M.H. van Ruijven, I.C. van der Horst, D.J. van Veldhuisen, and A.A. Voors Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients Eur. J. Heart Fail. 13 2011 76 82
30. J.W. Hartog, Y.M. Hummel, A.A. Voors, C.G. Schalkwijk, T. Miyata, R.M. Huisman, A.J. Smit, and D.J. Van Veldhuisen Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients J. Card. Fail. 14 2008 596 602
31. J.W. Hartog, R.M. van de Wal, C.G. Schalkwijk, T. Miyata, W. Jaarsma, H.W. Plokker, L.M. van Wijk, A.J. Smit, D.J. van Veldhuisen, and A.A. Voors Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction Eur. J. Heart Fail. 12 2010 397 403
32. N. Tahara, A. Tahara, A. Honda, Y. Nitta, N. Kodama, S. Yamagishi, and T. Imaizumi Molecular imaging of vascular inflammation Curr. Pharm. Des. 20 2014 2439 2447
33. S. Yamagishi, and T. Matsui Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker Front. Biosci. (Elite Ed.) 2 2010 1184 1195
34. J.W. Nin, A. Jorsal, I. Ferreira, C.G. Schalkwijk, M.H. Prins, H.H. Parving, L. Tarnow, P. Rossing, and C.D. Stehouwer Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study Diabetes 59 2010 2027 2032
35. K. Fujisawa, N. Katakami, H. Kaneto, T. Naka, M. Takahara, F. Sakamoto, Y. Irie, K. Miyashita, F. Kubo, T. Yasuda, T.A. Matsuoka, and I. Shimomura Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes Atherosclerosis 227 2013 425 428
36. D.J. Mulder, P.L. van Haelst, S. Gross, K. de Leeuw, J. Bijzet, R. Graaff, R.O. Gans, F. Zijlstra, and A.J. Smit Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products Atherosclerosis 197 2008 217 223
37. M. Nagano, K. Fukami, S. Yamagishi, K. Sakai, Y. Kaida, T. Matsumoto, T. Hazama, M. Tanaka, S. Ueda, and S. Okuda Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients Nephrology (Carlton) 16 2011 299 303
38. D.J. Mulder, J.F. de Boer, R. Graaff, R. de Vries, W. Annema, J.D. Lefrandt, A.J. Smit, U.J. Tietge, and R.P. Dullaart Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus Atherosclerosis 218 2011 102 106
39. H.L. Lutgers, R. Graaff, R. de Vries, A.J. Smit, and R.P. Dullaart Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease Eur. J. Clin. Investig. 40 2010 812 817
40. M.A. den Dekker, M. Zwiers, E.R. van den Heuvel, L.C. de Vos, A.J. Smit, C.J. Zeebregts, M. Oudkerk, R. Vliegenthart, J.D. Lefrandt, and D.J. Mulder Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis PLoS One 8 2013 e83084
41. M.J. Noordzij, J.D. Lefrandt, E.A. Loeffen, B.R. Saleem, R. Meerwaldt, H.L. Lutgers, A.J. Smit, and C.J. Zeebregts Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease Int. J. Cardiovasc. Imaging 28 2012 431 438
42. V. Rigalleau, A. Cougnard-Gregoire, S. Nov, C. Gonzalez, E. Maury, S. Lorrain, H. Gin, and P. Barberger-Gateau Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes J. Diabetes Complicat. 29 2015 270 274
43. M.J. Noordzij, D.J. Mulder, P.H. Oomen, T. Brouwer, J. Jager, M. Castro Cabezas, J.D. Lefrandt, and A.J. Smit Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus-a multi-centre study Diabet. Med. 29 2012 1556 1561
44. K. Tanaka, Y. Tani, J. Asai, F. Nemoto, Y. Kusano, H. Suzuki, Y. Hayashi, K. Asahi, M. Nakayama, T. Miyata, and T. Watanabe Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes Diabet. Med. 29 2012 492 500
45. H.L. Lutgers, E.G. Gerrits, R. Graaff, T.P. Links, W.J. Sluiter, R.O. Gans, H.J. Bilo, and A.J. Smit Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus Diabetologia 52 2009 789 797
46. K. Tanaka, T. Katoh, J. Asai, F. Nemoto, H. Suzuki, K. Asahi, K. Sato, M. Sakaue, T. Miyata, and T. Watanabe Relationship of skin autofluorescence to cardiovascular disease in Japanese hemodialysis patients Ther. Apher. Dial. 14 2010 334 340
47. Q. Chen, L. Dong, L. Wang, L. Kang, and B. Xu Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2 Biochem. Biophys. Res. Commun. 381 2009 192 197
48. H. Ueno, H. Koyama, S. Fukumoto, S. Tanaka, T. Shoji, T. Shoji, M. Emoto, H. Tahara, M. Inaba, R. Kakiya, T. Tabata, T. Miyata, and Y. Nishizawa Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease Metabolism 60 2011 453 459
49. S. Yamagishi, H. Fujimori, H. Yonekura, N. Tanaka, and H. Yamamoto Advanced glycation endproducts accelerate calcification in microvascular pericytes Biochem. Biophys. Res. Commun. 258 1999 353 357
50. A.Y. Wang, C.K. Wong, Y.Y. Yau, S. Wong, I.H. Chan, and C.W. Lam Skin autofluorescence associates with vascular calcification in chronic kidney disease Arterioscler. Thromb. Vasc. Biol. 34 2014 1784 1790
51. D.J. Mulder, P.L. van Haelst, R. Graaff, R.O. Gans, F. Zijlstra, and A.J. Smit Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events Neth. Heart J. 17 2009 162 168
52. J.W. Hartog, S. Gross, L.H. Oterdoom, R.M. van Ree, A.P. de Vries, A.J. Smit, J.P. Schouten, P.P. Nawroth, R.O. Gans, W.J. van Son, A. Bierhaus, and S.J. Bakker Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients Transplantation 87 2009 1069 1077
53. Y. Ohnuki, R. Nagano, S. Takizawa, S. Takagi, and T. Miyata Advanced glycation end products in patients with cerebral infarction Intern. Med. 48 2009 587 591
54. R. Meerwaldt, T.P. Links, R. Graaff, K. Hoogenberg, J.D. Lefrandt, J.W. Baynes, R.O. Gans, and A.J. Smit Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy Diabetologia 48 2005 1637 1644
55. A. Araszkiewicz, D. Naskret, P. Niedzwiecki, P. Samborski, B. Wierusz-Wysocka, and D. Zozulinska-Ziolkiewicz Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes Diabetes Technol. Ther. 13 2011 837 842
56. J. Vouillarmet, D. Maucort-Boulch, P. Michon, and C. Thivolet Advanced glycation end products assessed by skin autofluorescence: a new marker of diabetic foot ulceration Diabetes Technol. Ther. 15 2013 601 605
57. L.C. de Vos, M.J. Noordzij, D.J. Mulder, A.J. Smit, H.L. Lutgers, R.P. Dullaart, P.W. Kamphuisen, C.J. Zeebregts, and J.D. Lefrandt Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease Arterioscler. Thromb. Vasc. Biol. 33 2013 131 138
58. R. Graaff, S. Arsov, B. Ramsauer, M. Koetsier, N. Sundvall, G.E. Engels, A. Sikole, L. Lundberg, G. Rakhorst, and B. Stegmayr Skin and plasma autofluorescence during hemodialysis: a pilot study Artif. Organs 38 2014 515 518
59. J.W. Hartog, A.P. de Vries, H.L. Lutgers, R. Meerwaldt, R.M. Huisman, W.J. van Son, P.E. de Jong, and A.J. Smit Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease Ann. N. Y. Acad. Sci. 1043 2005 299 307
60. L.E. Crowley, C.P. Johnson, N. McIntyre, R.J. Fluck, C.W. McIntyre, M.W. Taal, and J.C. Leung Tissue advanced glycation end product deposition after kidney transplantation Nephron Clin. Pract. 124 2013 54 59
61. N.J. McIntyre, R.J. Fluck, C.W. McIntyre, and M.W. Taal Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3 Clin. J. Am. Soc. Nephrol. 6 2011 2356 2363
62. K. Tanaka, Y. Tani, J. Asai, F. Nemoto, Y. Kusano, H. Suzuki, Y. Hayashi, K. Asahi, T. Katoh, T. Miyata, and T. Watanabe Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients Nephrol. Dial. Transplant. 26 2011 214 220
63. K. Tanaka, M. Nakayama, M. Kanno, H. Kimura, K. Watanabe, Y. Tani, Y. Kusano, H. Suzuki, Y. Hayashi, K. Asahi, K. Sato, T. Miyata, and T. Watanabe Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study PLoS One 8 2013 e83799
64. S. Ueda, S. Yamagishi, M. Yokoro, and S. Okuda Role of asymmetric dimethylarginine in cardiorenal syndrome Curr. Pharm. Des. 20 2014 2448 2455
65. R. Ando, S. Ueda, S. Yamagishi, H. Miyazaki, Y. Kaida, K. Kaifu, M. Yokoro, Y. Nakayama, N. Obara, K. Fukami, M. Takeuchi, and S. Okuda Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction Diabetes Vasc. Dis. Res. 10 2013 436 441
66. I. Makulska, M. Szczepańska, D. Drozdz, D. Polak-Jonkisz, and D. Zwolińska Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease Pediatr. Nephrol. 30 2015 811 819
67. I. Makulska, M. Szczepańska, D. Drozdz, D. Polak-Jonkisz, and D. Zwolińska Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease Pediatr. Nephrol. 28 2013 121 128
68. J. Skrha Jr., J. Soupal, G. Loni Ekali, M. Prázný, M. Kalousová, J. Kvasnička, L. Landová, T. Zima, and J. Skrha Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus J. Diabetes Res. 2013 10.1155/2013/650694
69. E.G. Gerrits, H.L. Lutgers, N. Kleefstra, R. Graaff, K.H. Groenier, A.J. Smit, R.O. Gans, and H.J. Bilo Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications Diabetes Care 31 2008 517 521
70. S. Chabroux, F. Canouï-Poitrine, S. Reffet, G. Mills-Joncour, E. Morelon, C. Colin, and C. Thivolet Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy Diabetes Metab. 36 2010 152 157
71. M. Genevieve, A. Vivot, C. Gonzalez, C. Raffaitin, P. Barberger-Gateau, H. Gin, and V. Rigalleau Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus Diabetes Metab. 39 2013 349 354
72. T. Hirano, Y. Iesato, Y. Toriyama, A. Imai, D. Chiba, and T. Murata Correlation between diabetic retinopathy severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients J. Diabetes Complicat. 28 2014 729 734
73. T. Adachi, K. Fukami, S. Yamagishi, Y. Kaida, R. Ando, K. Sakai, H. Adachi, A. Otsuka, S. Ueda, K. Sugi, and S. Okuda Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients Nephrology (Carlton) 17 2012 689 694
74. J. Jiang, P. Chen, J. Chen, X. Yu, D. Xie, C. Mei, F. Xiong, W. Shi, W. Zhou, X. Liu, S. Sun, P. Zhang, X. Yang, Y. Zhang, Y. Zhang, X. Liang, Z. Zhang, Q. Lin, Y. Yu, T. Miyata, J. Tian, M. Liang, W. Luo, X. Xu, and F. Hou Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis Atherosclerosis 224 2012 187 194
75. R. Meerwaldt, J.W. Hartog, R. Graaff, R.J. Huisman, T.P. Links, N.C. den Hollander, S.R. Thorpe, J.W. Baynes, G. Navis, R.O. Gans, and A.J. Smit Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients J. Am. Soc. Nephrol. 16 2005 3687 3693
76. E.G. Gerrits, H.L. Lutgers, G.H. Smeets, K.H. Groenier, A.J. Smit, R.O. Gans, and H.J. Bilo Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients Nephron Extra 2 2012 184 191
77. H. Kimura, K. Tanaka, M. Kanno, K. Watanabe, Y. Hayashi, K. Asahi, H. Suzuki, K. Sato, M. Sakaue, H. Terawaki, M. Nakayama, T. Miyata, and T. Watanabe Skin autofluorescence predicts cardiovascular mortality in patients on chronic hemodialysis Ther. Apher. Dial. 18 2014 461 467
78. S. Arsov, L. Trajceska, W. van Oeveren, A.J. Smit, P. Dzekova, B. Stegmayr, A. Sikole, G. Rakhorst, and R. Graaff Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients Artif. Organs 37 2013 E114 E122
79. D. Siriopol, S. Hogas, G. Veisa, I. Mititiuc, C. Volovat, M. Apetrii, M. Onofriescu, I. Busila, M. Oleniuc, and A. Covic Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis Int. Urol. Nephrol. 47 2015 563 569
80. R. Meerwaldt, H.L. Lutgers, T.P. Links, R. Graaff, J.W. Baynes, R.O. Gans, and A.J. Smit Skin autofluorescence is a strong predictor of cardiac mortality in diabetes Diabetes Care 30 2007 107 112
81. L.C. de Vos, D.J. Mulder, A.J. Smit, R.P. Dullaart, N. Kleefstra, W.M. Lijfering, P.W. Kamphuisen, C.J. Zeebregts, and J.D. Lefrandt Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease Arterioscler. Thromb. Vasc. Biol. 34 2014 933 938
82. S.D. Fraser, P.J. Roderick, N.J. McIntyre, S. Harris, C.W. McIntyre, R.J. Fluck, and M.W. Taal Skin autofluorescence and all-cause mortality in stage 3 CKD Clin. J. Am. Soc. Nephrol. 9 2014 1361 1368
83. H. Corstjens, D. Dicanio, N. Muizzuddin, A. Neven, R. Sparacio, L. Declercq, and D. Maes Glycation associated skin autofluorescence and skin elasticity are related to chronological age and body mass index of healthy subjects Exp. Gerontol. 43 2008 663 667
84. E. Sugisawa, J. Miura, Y. Iwamoto, and Y. Uchigata Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes Diabetes Care 36 2013 2339 2345